Oral cancer treatment: developments in chemotherapy and beyond

Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Muller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20: 7 1759–1766

Baselga J (2001) The EGFR as a target for anticancer therapy–focus on cetuximab. Eur J Cancer 37: Suppl 4 S16–S22

Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, Raymond E, Maddox A-M, Kaye SB, Kieback D G, Harris A, Ochs J (2000) Continuous Administration of ZD1839 (Iressa), a Novel Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Patients with Five Selected Tumor Types: Evidence of Activity and Good Tolerability. Proc Am Soc Clin Oncol 19: 177

Cassidy J, Twelves C, Cameron D, Steward W, O'Byrne K, Jodrell D, Banken L, Goggin T, Jones D, Roos B, Bush E, Weidekamm E, Reigner B (1999) Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 44: 6 453–460

DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16: 7 2557–2567

Guengerich FP (1992) Characterisation of human P450 enzymes. FASEB J 6: 745–748

Kantarjian HM, Talpaz M (2001) Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol 28: 5 Suppl 17 9–18

Lamont EB, Schilsky Rl (1999) The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 5: 2289–2296

Lebovits AH, Strainn JJ, Schleifer SJ (1990) Patient non compliance with self-administered chemotherapy. Cancer 65: 17–22

Lee CR, Nicholson PW, Ledermann JA, Rustin GJ (1996) Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Eur J Gynaecol Oncol 17: 2 99–103

Lee CR, Nicholson PW, Souhami RL, Deshmukh AA (1992) Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 10: 6 1007–1013

Lee CR, Nicholson PW, Souhami RL, Slevin ML, Hall MR, Deshmukh AA (1993) Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 67: 3 630–634

Liu G, Franssen E, Fitch M, Warner E (1997) Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110–115

O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 12 2812–2823

Payne SA (1992) A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 35: 12 1505–1509

Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ, Allen LF, Nadler P, Bonomi P (2001) A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advancecd, EGFR-expressing, non-small cell lung cancer. Proc ASCO 20: 310

Polizzi D, Pratesi G, Monestiroli S, Tortoreto M, Zunino F, Bombardelli E, Riva A, Morazzoni P, Colombo T, d'Incalci M, Zucchetti M (2000) Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res 6: 5 2070–2074

Rose WC, Long BH, Fairchild CR, Lee FY, Kadow JF (2001) Preclinical Pharmacology of BMS-275183, an Orally Active Taxane. Clin Cancer Res 7: 7 2016–2021

Rajagonopalan S, Hanson-Painton O, Cooper DR (2000) Protein kinases as therapeutic targets. Pharma Res 17: 11 1345

Senzer NN, Soulieres D, Siu L, Agarwala S, Vokes E, Hidalgo M, Silberman S, Allen L, Ferrante K, Fishers D, Marsolais C, Nadler P (2001) Phase 2 elevation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc ASCO 20: 2

Sullivan SD, Mozaffari E, Johnson ES, Wolitz R, Follansbee SE (1996) An economic evaluation of oral compared with intravenoud ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus inj AIDS patients. Clin Therapeut 18: 546–558

Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K The Xeloda Colorectal Cancer Study Group (2001) Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 37: 5 597–604

van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 9291 1421–1423

von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, Richardson G, Steppert C, Riviere A, Camlett I, Lane S, Ross G (2001) Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19: 6 1743–1749